Q-omics provides the consensus-scored BPY2DP profile across patient tissues and cancer cell-line models. BPY2DP expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, BPY2DP is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, BPY2DP RNA expression shows 1,315 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight UCEC, and KIRC as cancer lineages where BPY2DP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPY2DP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BPY2DP survival associations across molecular data types. BPY2DP RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPY2DP RNA expression–survival associations across cancer types. High BPY2DP expression shows unfavorable associations in UCEC, KIRP, STAD, KIRC and LUAD, but favorable associations in HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for BPY2DP RNA expression.
This table summarizes BPY2DP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BPY2DP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BPY2DP shows higher tumor expression in KIRC. The KIRC box plot shows higher BPY2DP RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p = .010).
This table shows molecular features associated with BPY2DP in patient tissues and cancer cell lines. In patient samples, BPY2DP shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
